Table 3.
Comparison between FCM and FX treatment: Supplemental statistical analysis
| FCM FX Comparison FCM vs. FX | ||||||
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Difference | 95% CI of the difference | P value | ||
| Hb (g/dL) | 11.7 ± 0.8 | 11.6 ± 0.8 | 0.15 | -0.05 | 0.35 | 0.139 |
| TSAT (%) | 32.5 ± 13.4 | 22.6 ± 13.6 | 9.8 | 5.4 | 14.3 | 0.000 |
| EPO (monthly IU) | 25,069.1 ± 15,202 | 32,852.4 ± 22,473.7 | -7,783.3 | -12,866.2 | -2,700.4 | 0.004 |
| ERI (EPO dose/Hb) | 2,201 ± 1,374.3 | 2,936.4 ± 2,084.8 | -735.4 | -1,198.8 | -271.9 | 0.003 |
| Fe (μg/dL) | 68.7 ± 24.4 | 56.2 ± 17.6 | 12.6 | 2.9 | 22.3 | 0.013 |
| Transferrin (mg/dL) | 162.4 ± 29.1 | 190.2 ± 47.6 | -27.8 | -42.4 | -13.2 | 0.001 |
| Ferritin (ng/mL) | 772.5 ± 377.7 | 474.4 ± 361.8 | 298.1 | 150 | 446.2 | 0.000 |
| Albumin (g/dL) | 3.1 ± 0.3 | 3.2 ± 0.4 | -0.1 | -0.2 | 0 | 0.018 |
| PTH (pg/mL) | 365.7 ± 406.5 | 283 ± 293.1 | 82.7 | -7.8 | 173.3 | 0.072 |
| Ca (mg/dL) | 8.4 ± 0.5 | 8.7 ± 0.6 | -0.3 | -0.6 | -0.1 | 0.003 |
| P (mg/dL) | 4.6 ± 1.2 | 4.7 ± 1.3 | -0.1 | -0.5 | 0.3 | 0.667 |
| Uric acid (mg/dL) | 6.3 ± 1.2 | 6.5 ± 1.5 | -0.2 | -0.5 | 0.1 | 0.117 |
| Fibrinogen (mg/dL) | 331.4 ± 53.2 | 337.9 ± 67.6 | -6.5 | -31.8 | 18.9 | 0.602 |
| Necessity of EPO (%) | 77.8 ± 29.2 | 83.1 ± 27.7 | -5.3 | -10.8 | 0.3 | 0.063 |
| Occurrence TSAT < 20 (%) | 23.9 ± 25.9 | 47.9 ± 47.7 | -24.1 | -39.7 | -8.4 | 0.004 |
| Occurrence HB < 11 (%) | 27.7 ± 15.8 | 32.4 ± 22.4 | -4.7 | -12.2 | 2.8 | 0.211 |
Ca, serum calcium; FCM, ferric carboxymaltose; Fe, iron; FX, iron gluconate; EPO, erythropoietin; ERI, erythropoietin resistance index; Hb, hemoglobin; IU, international unit; P, serum phosphorus; PTH, parathyroid hormone; SD, standard deviation; TSAT, transferrin saturation.